Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.16 USD | -5.68% | +1.41% | -27.76% |
Financials (USD)
Sales 2024 * | 323M | Sales 2025 * | 420M | Capitalization | 409M |
---|---|---|---|---|---|
Net income 2024 * | -9M | Net income 2025 * | 49M | EV / Sales 2024 * | 0.58 x |
Net cash position 2024 * | 223M | Net cash position 2025 * | 342M | EV / Sales 2025 * | 0.16 x |
P/E ratio 2024 * |
-38.4
x | P/E ratio 2025 * |
10.9
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.44% |
Latest transcript on Esperion Therapeutics, Inc.
1 day | -5.68% | ||
1 week | +1.41% | ||
1 month | +5.88% | ||
3 months | -15.29% | ||
6 months | +50.00% | ||
Current year | -27.76% |
Managers | Title | Age | Since |
---|---|---|---|
Sheldon Koenig
CEO | Chief Executive Officer | 58 | 20-12-14 |
Director of Finance/CFO | 38 | 19-12-31 | |
JoAnne Foody
CTO | Chief Tech/Sci/R&D Officer | 59 | 21-06-27 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 52 | 22-04-27 | |
J. Carroll
CHM | Chairman | 74 | 22-05-31 |
Alan Fuhrman
BRD | Director/Board Member | 67 | 20-03-15 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 234 M€ | +8.48% | - | |
0.00% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 2.16 | -5.68% | 5,947,710 |
24-05-30 | 2.29 | +5.53% | 7,315,179 |
24-05-29 | 2.17 | +3.33% | 5,058,793 |
24-05-28 | 2.1 | -1.41% | 4,533,468 |
24-05-24 | 2.13 | -5.33% | 4,994,789 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.76% | 409M | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
-5.52% | 206B | |
+6.17% | 164B | |
-0.45% | 162B |
- Stock Market
- Equities
- ESPR Stock